In this task, you are given a question and a context passage. You have to answer the question based on the given passage.

[EX Q]: What ties together spiritual leader and editor?, Context: According to the New Jersey Press Association, several media entities refrain from using the term "ultra-Orthodox", including the Religion Newswriters Association; JTA, the global Jewish news service; and the Star-Ledger, New Jersey’s largest daily newspaper. The Star-Ledger was the first mainstream newspaper to drop the term. Several local Jewish papers, including New York's Jewish Week and Philadelphia's Jewish Exponent have also dropped use of the term. According to Rabbi Shammai Engelmayer, spiritual leader of Temple Israel Community Center in Cliffside Park and former executive editor of Jewish Week, this leaves "Orthodox" as "an umbrella term that designates a very widely disparate group of people very loosely tied together by some core beliefs."
[EX A]: Rabbi Shammai Engelmayer

[EX Q]: What is the parent agency for the Center for Drug Evaluation and Research?, Context: Possible improvements include clarification of clinical trial regulations by FDA. Furthermore, appropriate economic incentives could persuade pharmaceutical companies to invest in this endeavor. Antibiotic Development to Advance Patient Treatment (ADAPT) Act aims to fast track the drug development to combat the growing threat of 'superbugs'. Under this Act, FDA can approve antibiotics and antifungals treating life-threatening infections based on smaller clinical trials. The CDC will monitor the use of antibiotics and the emerging resistance, and publish the data. The FDA antibiotics labeling process, 'Susceptibility Test Interpretive Criteria for Microbial Organisms' or 'breakpoints', will provide accurate data to healthcare professionals. According to Allan Coukell, senior director for health programs at The Pew Charitable Trusts, "By allowing drug developers to rely on smaller datasets, and clarifying FDA's authority to tolerate a higher level of uncertainty for these drugs when making a risk/benefit calculation, ADAPT would make the clinical trials more feasible."
[EX A]: FDA

[EX Q]: What is the most common cause of death from infectious disease?, Context: Tuberculosis is the second-most common cause of death from infectious disease (after those due to HIV/AIDS). The total number of tuberculosis cases has been decreasing since 2005, while new cases have decreased since 2002. China has achieved particularly dramatic progress, with about an 80% reduction in its TB mortality rate between 1990 and 2010. The number of new cases has declined by 17% between 2004–2014. Tuberculosis is more common in developing countries; about 80% of the population in many Asian and African countries test positive in tuberculin tests, while only 5–10% of the US population test positive. Hopes of totally controlling the disease have been dramatically dampened because of a number of factors, including the difficulty of developing an effective vaccine, the expensive and time-consuming diagnostic process, the necessity of many months of treatment, the increase in HIV-associated tuberculosis, and the emergence of drug-resistant cases in the 1980s.
[EX A]:
those due to HIV/AIDS